E. Defrêne

Pharmacological characterization of the bradykinin B2 receptor: inter‐species variability and dissociation between binding and functional responses

D. Pruneau, J. Paquet, J. Luccarini, 1999, British journal of pharmacology.

Differential effects of selective- and pan-PPAR agonists on experimental steatohepatitis and hepatic macrophages.

F. Tacke, A. Geerts, J. Hundertmark, 2020, Journal of hepatology.

The new‐generation pan‐peroxisome proliferator‐activated receptor agonist IVA337 protects the liver from metabolic disorders and fibrosis

I. Leclercq, I. Konstantinova, J. Junien, 2017, Hepatology communications.

LF 16.0335, a novel potent and selective nonpeptide antagonist of the human bradykinin B2 receptor

D. Pruneau, J. Paquet, J. Luccarini, 1998, British journal of pharmacology.

Synthesis and pharmacological evaluation of dimer derivatives of the bradykinin receptor antagonist HOE-140.

M. Amblard, D. Pruneau, J. Paquet, 2009, The journal of peptide research : official journal of the American Peptide Society.

Pharmacological evidence for a single bradykinin B2 receptor in the guinea‐pig

D. Pruneau, J. Paquet, J. Luccarini, 1995, British journal of pharmacology.

Characterisation of bradykinin receptors from juvenile pig coronary artery.

D. Pruneau, J. Paquet, J. Luccarini, 1996, European journal of pharmacology.

Pharmacological profile of LF 16-0687, a new potent non-peptide bradykinin B2 receptor antagonist.

D. Pruneau, J. Paquet, J. Luccarini, 1999, Immunopharmacology.

In vitro and in vivo effects of the new nonpeptide bradykinin B2 receptor antagonist, LF 16‐0335C, on guinea‐pig and rat kinin receptors

D. Pruneau, J. Paquet, J. Luccarini, 1999, Fundamental & clinical pharmacology.

Pharmacological and molecular evidence for kinin B1 receptor expression in urinary bladder of cyclophosphamide‐treated rats

D. Pruneau, J. Paquet, J. Luccarini, 1999, British journal of pharmacology.